查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2040509

藥物檢測市場規模、佔有率和趨勢分析報告：按產品、檢體、藥物、最終用途、地區和細分市場分類（2026-2033 年）

Drug Testing Market Size, Share & Trends Analysis Report By Product, By Sample, By Drug, By End-use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

藥物檢測市場概況

全球藥物檢測市場預計到 2025 年將價值 70.9 億美元，預計到 2033 年將達到 115.5 億美元。

預計2026年至2033年，該市場將以6.32%的複合年成長率成長。全球藥物濫用問題的日益嚴重推動了對檢測解決方案需求的成長。

此外，政府機構出於安全原因強制進行酒精和藥物檢測的嚴格規定，以及加強對藥物濫用的監測和打擊力度，預計將進一步促進市場成長。

隨著全球藥物濫用問題的日益嚴重，對藥物檢測解決方案的需求也急劇成長。根據美國藥物濫用和精神衛生管理局 (SAMHSA) 發布的《2024 年全國藥物使用與健康調查》，約有 7,360 萬 12 歲及以上的美國人（佔總人口的 25.5%）報告在過去一年中使用過非法藥物。大麻仍然是最常用的非法藥物，約有 6,420 萬使用者，其次是致幻劑、處方鴉片和可卡因。持續不斷的鴉片類藥物危機也加劇了醫療保健、職場和執法機關部門對監測和檢測項目的需求。美國疾病管制與預防中心 (CDC) 估計，2023 年美國記錄在案的藥物過量死亡人數將超過 10.7 萬，凸顯了藥物濫用對公眾健康的嚴重影響。藥物濫用和過量用藥的增加推動了美國藥物檢測產業的成長，政府、雇主和醫療保健提供者都在推動實施定期藥物篩檢和監測計畫。

此外，酒精和毒品相關死亡人數的驚人成長凸顯了可靠檢測方案的迫切需求，並推動了對創新技術和服務的需求，以支持醫療保健和公共安全部門開展藥物濫用檢測、治療和預防工作。根據世界衛生組織2024年6月發布的報告，每年有超過300萬人死於酒精和毒品使用，其中男性受影響最大。在這些死亡病例中，260萬例歸因於酒精，60萬例歸因於精神藥物。報告也指出，全球約有4億人患有酒精使用障礙，其中2.09億人有成癮。雖然一些地區的酒精相關死亡率正在下降，但整體數字仍然高得驚人，尤其是在低收入國家。報告呼籲採取緊急行動，減少酒精和毒品消費，改善治療途徑，並強調需要進行協調一致的全球宣傳宣傳活動，加強醫療保健系統的治療能力，以實現2033年永續發展目標3.5。

增加治療項目的資源投入可能會導致對檢測服務的需求增加，以監測治療的依從性和有效性。更重視解決物質使用障礙問題，尤其是在服務不足的人群中，可能會推動技術和調查方法的創新。此外，全面的鴉片類藥物成癮康復舉措將增加對準確篩檢以防止濫用的需求，最終促進市場成長。 2024年7月，拜登-哈里斯政府撥款4,510萬美元擴大物質使用疾患服務。重點措施包括：為患有物質使用少數族群的無家可歸者提供750萬美元，為愛滋病毒/愛滋病高風險少數族裔提供400萬美元，以及為綜合鴉片類藥物康復中心提供170萬美元。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：藥物檢測市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 藥物檢測市場分析工具

第4章：藥物檢測市場：產品特定估算與趨勢分析

  • 按產品分類的市場佔有率，2025 年和 2033 年
  • 全球藥物檢測市場：依產品分類，展望
  • 市場規模、預測與趨勢分析，2021-2033年
    • 消耗品
    • 裝置
    • 快速檢測裝置
    • 服務

第5章：藥物檢測市場：依樣本類型分類的檢體與趨勢分析

  • 按檢體類型分類的市場佔有率，2025 年和 2033 年
  • 全球藥物檢測市場：依檢體類型分類，展望
  • 市場規模、預測與趨勢分析，2021-2033年
    • 尿液檢體
    • 口腔液樣本
    • 頭髮樣本
    • 其他樣本

第6章：藥物檢測市場：依藥物類型分類的估算與趨勢分析

  • 按藥物類型分類的市場佔有率，2025 年和 2033 年
  • 全球藥物檢測市場：依藥物類型分類，展望
  • 市場規模、預測與趨勢分析，2021-2033年
    • 酒精
    • 大麻/醫用大麻
    • 古柯鹼
    • 鴉片類藥物
    • 安非他命和甲基安非他命
    • LSD
    • 其他

第7章：藥物檢測市場：依最終用途分類的估算與趨勢分析

  • 按最終用途分類的市場佔有率（2025 年和 2033 年）
  • 全球藥物檢測市場：按最終用途分類的展望
  • 市場規模、預測與趨勢分析，2021-2033年
    • 藥物檢測實驗室
    • 職場
    • 醫院
    • 其他

第8章：藥物檢測市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 全球市場概述（按地區分類）
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第9章 競爭情勢

  • 主要市場參與企業近期趨勢及影響分析
  • 公司和競爭對手的分類
  • 供應商情況
    • 主要銷售代理商和通路夥伴名單
    • Key customers
    • Key company market share analysis, 2025
    • Quest Diagnostics Incorporated
    • Abbott
    • F. Hoffmann-La Roche Ltd.
    • Quidel Corporation
    • Thermo Fisher Scientific, Inc
    • Siemens Healthcare GmbH
    • Bio-Rad Laboratories, Inc.
    • Agilent Technologies, Inc.
    • Laboratory Corporation of America Holdings
    • Clinical Reference Laboratory, Inc.
    • Cordant Health Solutions
Product Code: GVR-4-68039-364-2

Drug Testing Market Summary

The global drug testing market size was estimated at USD 7.09 billion in 2025 and is projected to reach USD 11.55 billion by 2033, growing at a CAGR of 6.32% from 2026 to 2033. The rising prevalence of substance abuse worldwide has increased the demand for testing solutions.

In addition, strict regulations from various government bodies requiring alcohol and substance testing for safety reasons, along with increased initiatives to monitor and address substance abuse, are anticipated to further enhance market growth.

The rising global rates of substance abuse have considerably increased the demand for testing solutions. According to the Substance Abuse and Mental Health Services Administration (SAMHSA) 2024 National Survey on Drug Use and Health, about 73.6 million Americans aged 12 or older (25.5%) reported using illicit drugs in the past year. Cannabis remains the most commonly used illicit drug, with around 64.2 million users, followed by substances such as hallucinogens, prescription opioids, and cocaine. The ongoing opioid crisis has also increased the need for monitoring and testing programs across healthcare, workplace, and law enforcement sectors. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded over 107,000 drug overdose deaths in 2023, highlighting the serious public health impact of drug misuse. These rising cases of substance misuse and overdose are encouraging governments, employers, and healthcare providers to adopt regular drug screening and monitoring programs, which is supporting the growth of the U.S. drug testing industry.

Moreover, the alarming rise in alcohol and substance-related deaths emphasizes the urgent need for reliable testing solutions, driving demand for innovative technologies and services to support substance abuse detection, treatment, and prevention efforts in healthcare and public safety sectors. In June 2024, WHO report shows that over 3 million annual deaths are linked to alcohol and substance use, predominantly affecting men. Of these, 2.6 million deaths are due to alcohol, while 0.6 million are attributed to psychoactive drugs. The report highlights that around 400 million people suffer from alcohol use disorders globally, with 209 million experiencing dependence. Despite some declines in alcohol-related death rates, the overall figures remain alarmingly high, especially in low-income countries. The report calls for urgent actions to reduce alcohol and drug consumption and improve access to treatment, emphasizing the need for a coordinated global advocacy campaign and enhanced treatment capabilities in healthcare systems to achieve Sustainable Development Goal 3.5 by 2033.

Increased resources for treatment programs may lead to a higher demand for testing services to monitor compliance and effectiveness of treatments. The emphasis on addressing substance use disorders, especially among underserved populations, can spur innovations in technologies and methodologies. Furthermore, with comprehensive opioid recovery initiatives, there may be a greater need for accurate screening to prevent misuse, ultimately supporting growth in the market. In July 2024, The Biden-Harris Administration has awarded USD 45.1 million to expand services for substance use disorders. Key initiatives include USD 7.5 million for homeless individuals with substance use disorders, USD 4 million for minorities at high risk for HIV/AIDS, and USD 1.7 million for comprehensive opioid recovery centers.

Global Drug Testing Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global drug testing market report based on product, sample, drug, end-use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Consumables
  • Instruments
  • Rapid Testing Devices
  • Services
  • Sample Outlook (Revenue, USD Million, 2021 - 2033)
  • Urine Samples
  • Oral Fluid Samples
  • Hair Samples
  • Other Samples
  • Drug Outlook (Revenue, USD Million, 2021 - 2033)
  • Alcohol
  • Cannabis/Marijuana
  • Cocaine
  • Opioids
  • Amphetamine & Methamphetamine
  • LSD
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Drug Testing Laboratories
  • Workplaces
  • Hospitals
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Sample
    • 1.2.3. Drug
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Sample outlook
    • 2.2.3. Drug outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Drug Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. High prevalence of substance abuse
      • 3.2.1.2. Stringent laws mandating alcohol and drug testing
      • 3.2.1.3. Increasing government initiatives to monitor substance abuse
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Drug testing is considered a violation of privacy rights in some countries
  • 3.3. Drug Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Drug Testing Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Drug Testing Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Consumables
      • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Instruments
      • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Rapid Testing Devices
      • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.4. Services
      • 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Drug Testing Market: Sample Estimates & Trend Analysis

  • 5.1. Sample Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Drug Testing Market by Sample Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Urine samples
      • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Oral fluid samples
      • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3. Hair samples
      • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.4. Other Samples
      • 5.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Drug Testing Market: Drug Estimates & Trend Analysis

  • 6.1. Drug Market Share, 2025 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Drug Testing Market by Drug Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 6.4.1. Alcohol
      • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 6.4.2. Cannabis/Marijuana
      • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. Cocaine
      • 6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.4. Opioids
      • 6.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.5. Amphetamine & Methamphetamine
      • 6.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.6. LSD
      • 6.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.7. Others
      • 6.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Drug Testing Market: End use Estimates & Trend Analysis

  • 7.1. Ens Use Market Share, 2025 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Global Drug Testing Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 7.4.1. Drug Testing Laboratories
      • 7.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 7.4.2. Workplaces
      • 7.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. Hospitals
      • 7.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.4. Others
      • 7.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Drug Testing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2025
    • 9.3.4. Quest Diagnostics Incorporated
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Abbott
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. F. Hoffmann-La Roche Ltd.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Quidel Corporation
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Thermo Fisher Scientific, Inc
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Siemens Healthcare GmbH
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Bio-Rad Laboratories, Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Agilent Technologies, Inc.
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Laboratory Corporation of America Holdings
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Clinical Reference Laboratory, Inc.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Cordant Health Solutions
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of abbreviation
  • Table 3 North America drug testing market, by region, 2021 - 2033 (USD Million)
  • Table 4 North America drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 5 North America drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 6 North America drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 7 North America drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 8 U.S. drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 9 U.S. drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 10 U.S. drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 11 U.S. drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 12 Canada drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 13 Canada drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 14 Canada drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 15 Canada drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 16 Mexico drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 17 Mexico drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 18 Mexico drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 19 Mexico drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 20 Europe drug testing market, by region, 2021 - 2033 (USD Million)
  • Table 21 Europe drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 22 Europe drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 23 Europe drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 24 Europe drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 25 Germany drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 26 Germany drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 27 Germany drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 28 Germany drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 29 UK drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 30 UK drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 31 UK drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 32 UK drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 33 France drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 34 France drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 35 France drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 36 France drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 37 Italy drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 38 Italy drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 39 Italy drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 40 Italy drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 41 Spain drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 42 Spain drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 43 Spain drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 44 Spain drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 45 Denmark drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 46 Denmark drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 47 Denmark drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 48 Denmark drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 49 Sweden drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 50 Sweden drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 51 Sweden drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 52 Sweden drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 53 Norway drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 54 Norway drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 55 Norway drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 56 Norway drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 57 Asia Pacific drug testing market, by region, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 59 Asia Pacific drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 60 Asia Pacific drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 62 China drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 63 China drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 64 China drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 65 China drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 66 Japan drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 67 Japan drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 68 Japan drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 69 Japan drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 70 India drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 71 India drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 72 India drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 73 India drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 74 South Korea drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 75 South Korea drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 76 South Korea drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 77 South Korea drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 78 Australia drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 79 Australia drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 80 Australia drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 81 Australia drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 82 Thailand drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 83 Thailand drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 84 Thailand drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 85 Thailand drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 86 Latin America drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 87 Latin America drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 88 Latin America drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 89 Latin America drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 90 Brazil drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 91 Brazil drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 92 Brazil drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 93 Brazil drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 94 Argentina drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 95 Argentina drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 96 Argentina drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 97 Argentina drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 98 MEA drug testing market, by region, 2021 - 2033 (USD Million)
  • Table 99 MEA drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 100 MEA drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 101 MEA drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 102 MEA drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 103 South Africa drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 104 South Africa drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 105 South Africa drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 106 South Africa drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 107 Saudi Arabia drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 108 Saudi Arabia drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 109 Saudi Arabia drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 110 Saudi Arabia drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 111 UAE drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 112 UAE drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 113 UAE drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 114 UAE drug testing market, by end use, 2021 - 2033 (USD Million)
  • Table 115 Kuwait drug testing market, by product, 2021 - 2033 (USD Million)
  • Table 116 Kuwait drug testing market, by sample, 2021 - 2033 (USD Million)
  • Table 117 Kuwait drug testing market, by drug, 2021 - 2033 (USD Million)
  • Table 118 Kuwait drug testing market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Pathology Laboratories market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Drug testing market: Product movement analysis
  • Fig. 12 Drug testing market: Product outlook and key takeaways
  • Fig. 13 Consumables market estimates and forecast, 2021 - 2033
  • Fig. 14 Instruments estimates and forecast, 2021 - 2033
  • Fig. 15 Rapid Testing Devices market estimates and forecast, 2021 - 2033
  • Fig. 16 Services estimates and forecast, 2021 - 2033
  • Fig. 17 Drug testing market: Sample movement Analysis
  • Fig. 18 Drug testing market: Sample outlook and key takeaways
  • Fig. 19 Urine samples market estimates and forecasts, 2021 - 2033
  • Fig. 20 Hair samples market estimates and forecasts, 2021 - 2033
  • Fig. 21 Oral fluid samples market estimates and forecasts, 2021 - 2033
  • Fig. 22 Others samples market estimates and forecasts, 2021 - 2033
  • Fig. 23 Drug testing market: drug movement analysis
  • Fig. 24 Drug testing market: drug outlook and key takeaways
  • Fig. 25 Alcohol market estimates and forecasts, 2021 - 2033
  • Fig. 26 Cannabis/Marijuana market estimates and forecasts, 2021 - 2033
  • Fig. 27 Cocaine market estimates and forecasts, 2021 - 2033
  • Fig. 28 Opioids market estimates and forecasts, 2021 - 2033
  • Fig. 29 Amphetamine & methamphetamine market estimates and forecasts, 2021 - 2033
  • Fig. 30 Other market estimates and forecasts, 2021 - 2033
  • Fig. 31 Drug testing market: end use movement analysis
  • Fig. 32 Drug testing market: end use outlook and key takeaways
  • Fig. 33 Drug testing laboratories market estimates and forecasts, 2021 - 2033
  • Fig. 34 Workplaces market estimates and forecasts, 2021 - 2033
  • Fig. 35 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig. 36 Others market estimates and forecasts, 2021 - 2033
  • Fig. 37 Global drug testing market: Regional outlook and key takeaways
  • Fig. 38 North America market estimates and forecasts, 2021 - 2033
  • Fig. 39 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 40 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 41 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 42 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 43 UK market estimates and forecasts, 2021 - 2033
  • Fig. 44 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 45 France market estimates and forecasts, 2021 - 2033
  • Fig. 46 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 47 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 48 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 49 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 50 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 51 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 52 China market estimates and forecasts, 2021 - 2033
  • Fig. 53 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 54 India market estimates and forecasts, 2021 - 2033
  • Fig. 55 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 56 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 57 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 58 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 59 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 60 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 61 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 62 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 63 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 64 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 65 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 66 Market share of key market players- drug testing market